Lipella Pharmaceuticals (NASDAQ:LIPO) Coverage Initiated at Maxim Group

Investment analysts at Maxim Group assumed coverage on shares of Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) in a note issued to investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $2.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 167.85% from the company’s previous […]

Related Keywords

,Lipella Pharmaceuticals Inc ,Sigma Securities ,Lipella Pharmaceuticals ,News Ratings For Lipella Pharmaceuticals Daily ,Nasdaq ,Institutional Trading Of Lipella Pharmaceuticals ,Maxim Group ,Lipella Pharmaceuticals Stock ,Securities Exchange Commission ,Get Free Report ,Free Report ,Pharmaceuticals Inc ,Lipella Pharmaceuticals Daily ,Nasdaq Lipo ,Lipo ,Medical ,Initiated Coverage ,